Swiss Insurance Stock News

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Stadler Rail AG's ( VTX:SRAIL ) price-to-earnings (or "P/E") ratio of 64.6x might make it look like a strong sell right...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

There wouldn't be many who think Burckhardt Compression Holding AG's ( VTX:BCHN ) price-to-earnings (or "P/E") ratio of...

Schindler Holding (SWX:SCHN) posted a steady 8.1% earnings growth over the past year, topping its five-year average of 5.9%. Profit margins improved from 8.1% to 9.1%. Earnings are forecast to rise 7.93% annually and revenue growth is expected at 4.3% per year, slightly ahead of the Swiss market’s 4% average. However, this pace still trails the broader market’s projected 10.6% earnings growth. Key investor takeaways include the margin gains and above-market revenue trajectory, balanced by...

Thinking about what to do with Alcon stock? You are not alone. Plenty of investors are eyeing those recent movements and asking themselves whether this is a dip to buy or a sign to tread carefully. After several years of steady if unspectacular growth, Alcon’s shares have taken a hit this year, dropping 20.0% year-to-date and sitting about 25.2% lower than they were at this time last year. Still, the stock has edged up 2.7% in the past week and gained 3.7% over the last month. This has...

Sika (SWX:SIKA) delivered earnings forecast to grow at 10% per year, with revenue set to rise by 4.7% annually, outpacing the broader Swiss market’s projected 4% growth rate. Over the past five years, earnings have climbed by 6.9% each year, and the company has maintained a net profit margin of 10.5%, matching the prior period. These numbers, paired with Sika’s high-quality earnings profile and only minor risk concerns, provide investors with a constructive outlook anchored by continued...

Novartis recently announced that Cosentyx met all primary and secondary endpoints in the Phase III REPLENISH trial, showing statistically significant and clinically meaningful sustained remission at Week 52 for adults with polymyalgia rheumatica. This achievement highlights the company's momentum in late-stage innovation, as similar positive clinical outcomes were reported across other major therapies in immunology, oncology, and rare diseases. Next, we'll explore how Cosentyx's late-stage...

Trying to figure out what to do with UBS Group stock? You’re not alone. Whether you’re pondering a first investment or reconsidering your current position, recent share price swings have plenty of investors pausing to re-examine their next move. Over the past week, UBS shares inched up by 0.4%. Zoom out to the last month and they’re actually down 8.4%. Despite this, the stock is sitting on gains of 6.8% for the year to date. Looking at the last three years, UBS has risen over 100%. The...

Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...

Nestlé (SWX:NESN) shares have seen modest movement in recent weeks, catching the attention of market watchers who are weighing up its evolving fundamentals. Investors are considering both recent returns and the company’s growth drivers in the food and beverage space. See our latest analysis for Nestlé. While Nestlé’s 12.4% 1-month share price return signals a sharp rebound for the stock, its 1-year total shareholder return remains slightly in the red and longer-term returns have lagged the...

Alcon (SWX:ALC) shares have shown mild gains over the past week, rising just under 3%. The stock's recent movement reflects ongoing investor interest, especially as the company’s fundamentals have experienced steady, if unspectacular, growth this year. See our latest analysis for Alcon. This recent uptick comes after a challenging stretch for Alcon, with the shares still down nearly 20% year-to-date and the one-year total shareholder return reflecting a 25% loss. While recent gains hint at...

Roche recently secured FDA approval for Gazyva as a treatment for lupus nephritis, alongside positive late-stage clinical trial data and a favorable recommendation from the European Medicines Agency. This expansion into autoimmune kidney diseases, along with continued progress in key clinical programs, highlights Roche's increasing presence in high-need therapeutic areas beyond its traditional oncology focus. We will explore how these advancements in Roche's immunology pipeline may impact...

Key Insights Kardex Holding's estimated fair value is CHF323 based on 2 Stage Free Cash Flow to Equity Current share...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...

UBS Group (SWX:UBSG) shares caught some attention this week after posting a modest 0.7% uptick in the last trading session. Investors may be eyeing recent trends as they weigh the stock’s longer-term performance. See our latest analysis for UBS Group. After a steady climb earlier this year, UBS Group’s share price momentum has eased, with a 1-month price return of -9.33%. Still, the stock’s 12.21% total shareholder return over the past year highlights the impact of improving fundamentals and...

Novartis (SWX:NOVN) shares have seen a mild pullback over the past day, despite steady gains for the month and year. Investors seem to be weighing recent momentum in revenue and earnings while considering broader sector trends. See our latest analysis for Novartis. Novartis has been quietly building positive momentum, notching a 12.6% share price return over the last quarter and a total shareholder return of 10.2% for the past year. Growth in underlying earnings and steady sector-wide...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Kuehne + Nagel International (SWX:KNIN) reported a net profit margin of 4.5%, down from 5% the previous year. This marks a modest uptick in earnings with 1.3% growth after several years of decline. While current profitability has improved, the company’s shares are trading at a Price-To-Earnings ratio of 16.1x, which represents a premium to industry peers but remains below intrinsic value as indicated by discounted cash flow estimates. Soft margins, ongoing profit growth, and concerns about...

Deciding what to do with Nestlé stock these days is far from straightforward. If you’ve held shares, you know the ride hasn't been smooth. Just look at the numbers: while the stock has bounced back 7.5% over the last week and surged 14.2% over the past month, it’s still down about 0.7% over the last year, and even further over three and five years. The question is, does this momentum signal a long-awaited turnaround or is there more volatility ahead? Recent headlines have added fuel to the...

As the European markets navigate a landscape of mixed economic signals, with the pan-European STOXX Europe 600 Index seeing slight gains amidst dovish comments from U.S. Fed Chair Jerome Powell, investors are increasingly focusing on income-generating opportunities like dividend stocks. In this environment, selecting stocks that offer robust dividend yields can be an attractive strategy for those looking to balance potential market volatility with steady income streams.

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

ABB (SWX:ABBN) has seen intriguing movement in its stock performance over the past month, gaining 2% and rising 8% in the past 3 months. Shareholders are likely watching how these returns compare to peers in the capital goods sector. See our latest analysis for ABB. ABB’s latest 1-year total shareholder return of 21.5% underscores strong underlying momentum, especially with a 17% share price gain year-to-date. While the past week was choppy, the bigger story is the company's steady multi-year...